Cytokinetics Wins Health Canada Approval for Myqorzo Heart Drug
MT newswire2026/10/19 12:34Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
08:34 AM EDT, 10/19/2026 (MT Newswires) -- Cytokinetics (CYTK) said Monday that Health Canada approved Myqorzo, or aficamten, to treat adults with symptomatic obstructive hypertrophic cardiomyopathy classified as New York Heart Association Class II-III. The once-daily oral drug is designed to reduce excessive heart muscle contraction and obstruction of blood flow from the heart, the company said. The approval was supported by phase 3 SEQUOIA-HCM trial results, which showed improved exercise capacity after 24 weeks, the company added.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
BUZZ-T1 Energy’s stock price plummets due to plan to sell $100 million in shares
路透社•2026/11/16 16:36

BUZZ-MiniMed shares rise as its tubeless insulin pump receives FDA approval
路透社•2026/11/16 16:11
Crypto prices
MoreBitcoin
BTC
$64,718.86
+0.27%
Ethereum
ETH
$1,824.89
+0.93%
Tether USDt
USDT
$0.9991
-0.03%
BNB
BNB
$588.96
-0.08%
USDC
USDC
$0.9998
+0.01%
XRP
XRP
$0.9564
+0.77%
Solana
SOL
$71.15
-0.16%
TRON
TRX
$0.3061
+0.55%
Hyperliquid
HYPE
$66.95
+0.06%
Zcash
ZEC
$887.46
-1.08%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now